$CNTX News

Context Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Jan. 25 To Regain Compliance

Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26

Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer

Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate

Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer

Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Context Therapeutics to Participate in Upcoming Investor Conferences

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target